Barclays PLC Takes Position in Pharvaris (NASDAQ:PHVS)

Barclays PLC acquired a new stake in shares of Pharvaris (NASDAQ:PHVS) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 5,700 shares of the company’s stock, valued at approximately $106,000.

Other hedge funds also recently made changes to their positions in the company. Novo Holdings A S increased its stake in shares of Pharvaris by 47.7% in the second quarter. Novo Holdings A S now owns 1,725,000 shares of the company’s stock worth $32,430,000 after buying an additional 556,970 shares during the last quarter. Deerfield Management Company L.P. Series C increased its stake in shares of Pharvaris by 31.6% in the second quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company’s stock worth $26,269,000 after buying an additional 335,687 shares during the last quarter. Patient Square Capital LP bought a new stake in shares of Pharvaris in the third quarter worth $4,488,000. State Street Corp bought a new stake in shares of Pharvaris in the third quarter worth $1,000,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Pharvaris in the third quarter worth $906,000.

Pharvaris Price Performance

PHVS stock opened at $18.54 on Thursday. Pharvaris has a 1-year low of $15.37 and a 1-year high of $33.00. The firm has a fifty day moving average price of $20.38 and a two-hundred day moving average price of $19.36. The firm has a market cap of $590.31 million, a price-to-earnings ratio of -6.62 and a beta of -3.06.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.